Recce Pharmaceuticals Croissance future
Future contrôle des critères 0/6
Recce Pharmaceuticals's revenue and earnings are forecast to decline at 2% and 53.4% per annum respectively while EPS is expected to decline by 39.6% per annum.
Informations clés
-53.4%
Taux de croissance des bénéfices
-39.6%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 54.6% |
| Taux de croissance des recettes | -2.0% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 17 Jul 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now
Nov 01
Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation
Feb 13We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely
Jul 28Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans
Dec 07We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely
Aug 03Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans
Mar 08Need To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares
Feb 01Could The Recce Pharmaceuticals Ltd (ASX:RCE) Ownership Structure Tell Us Something Useful?
Dec 09Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 6/30/2026 | 5 | -43 | -43 | -10 | 2 |
| 6/30/2025 | 7 | -11 | -11 | -8 | 2 |
| 6/30/2024 | 5 | -18 | -13 | -13 | N/A |
| 3/31/2024 | 6 | -14 | -11 | -11 | N/A |
| 12/31/2023 | 7 | -11 | -9 | -9 | N/A |
| 9/30/2023 | 6 | -12 | -11 | -11 | N/A |
| 6/30/2023 | 4 | -13 | -13 | -13 | N/A |
| 3/31/2023 | 4 | -14 | -14 | -14 | N/A |
| 12/31/2022 | 3 | -15 | -15 | -14 | N/A |
| 9/30/2022 | 3 | -13 | -12 | -12 | N/A |
| 6/30/2022 | 3 | -11 | -9 | -9 | N/A |
| 3/31/2022 | 2 | -10 | -8 | -8 | N/A |
| 12/31/2021 | 1 | -8 | -7 | -7 | N/A |
| 9/30/2021 | 1 | -11 | -8 | -8 | N/A |
| 6/30/2021 | 2 | -14 | -8 | -8 | N/A |
| 3/31/2021 | 1 | -13 | -8 | -8 | N/A |
| 12/31/2020 | 1 | -13 | -8 | -8 | N/A |
| 9/30/2020 | 1 | -9 | -6 | -6 | N/A |
| 6/30/2020 | 1 | -4 | -4 | -4 | N/A |
| 3/31/2020 | 1 | -4 | -3 | -3 | N/A |
| 12/31/2019 | 1 | -3 | -3 | -3 | N/A |
| 9/30/2019 | 1 | -3 | -3 | -3 | N/A |
| 6/30/2019 | 1 | -3 | -3 | -3 | N/A |
| 3/31/2019 | 1 | -2 | -2 | -2 | N/A |
| 12/31/2018 | 2 | -2 | -2 | -2 | N/A |
| 9/30/2018 | 1 | -2 | -2 | -2 | N/A |
| 6/30/2018 | 1 | -2 | -2 | -2 | N/A |
| 3/31/2018 | 1 | -2 | N/A | -2 | N/A |
| 12/31/2017 | 1 | -3 | N/A | -2 | N/A |
| 9/30/2017 | 0 | -3 | N/A | -2 | N/A |
| 6/30/2017 | 0 | -3 | N/A | -2 | N/A |
| 3/31/2017 | 0 | -3 | N/A | -2 | N/A |
| 12/31/2016 | 0 | -2 | N/A | -2 | N/A |
| 9/30/2016 | 0 | -4 | N/A | -2 | N/A |
| 6/30/2016 | 0 | -5 | N/A | -2 | N/A |
| 3/31/2016 | 0 | -5 | N/A | -1 | N/A |
| 12/31/2015 | 0 | -4 | N/A | -1 | N/A |
| 9/30/2015 | 0 | -2 | N/A | 0 | N/A |
| 6/30/2015 | 0 | 0 | N/A | 0 | N/A |
| 6/30/2014 | 0 | 0 | N/A | N/A | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: RCE is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: RCE is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: RCE is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: RCE's revenue is expected to decline over the next 3 years (-2% per year).
Croissance élevée des revenus: RCE's revenue is forecast to decline over the next 3 years (-2% per year).
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if RCE's Return on Equity is forecast to be high in 3 years time